skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 68,597  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Refined by: subject: Adult remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Material Type:
Article
Add to My Research

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Journal of clinical oncology, 2019-02, Vol.37 (4), p.278-285 [Peer Reviewed Journal]

2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.18.01585 ;PMID: 30550363

Full text available

2
miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells
Material Type:
Article
Add to My Research

miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells

PloS one, 2013-03, Vol.8 (3), p.e60317-e60317 [Peer Reviewed Journal]

COPYRIGHT 2013 Public Library of Science ;2013 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Chen et al 2013 Chen et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0060317 ;PMID: 23555954

Full text available

3
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Material Type:
Article
Add to My Research

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2027071 ;PMID: 32955177

Full text available

4
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Material Type:
Article
Add to My Research

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1910231 ;PMID: 31562796

Full text available

5
Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Material Type:
Article
Add to My Research

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2022-01, Vol.386 (3), p.241-251 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2112431 ;PMID: 34534430

Full text available

6
Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer
Material Type:
Article
Add to My Research

Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer

PloS one, 2012-04, Vol.7 (4), p.e35065-e35065 [Peer Reviewed Journal]

COPYRIGHT 2012 Public Library of Science ;COPYRIGHT 2012 Public Library of Science ;2012 Lv et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Lv et al. 2012 ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0035065 ;PMID: 22493729

Full text available

7
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Material Type:
Article
Add to My Research

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

The lancet oncology, 2018-01, Vol.19 (1), p.139-148 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Jan 1, 2018 ;2018. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30729-5 ;PMID: 29174310

Full text available

8
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Material Type:
Article
Add to My Research

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-11, Vol.377 (20), p.1919-1929 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1709937 ;PMID: 28885881

Full text available

9
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer
Material Type:
Article
Add to My Research

Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer

British journal of cancer, 2019-09, Vol.121 (6), p.490-496 [Peer Reviewed Journal]

Copyright Nature Publishing Group Sep 2019 ;The Author(s), under exclusive licence to Cancer Research UK 2019 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-019-0541-3 ;PMID: 31388183

Full text available

10
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Material Type:
Article
Add to My Research

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1917346 ;PMID: 32997907

Full text available

11
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Material Type:
Article
Add to My Research

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1801005 ;PMID: 29658856

Full text available

12
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial
Material Type:
Article
Add to My Research

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial

BMC cancer, 2020-08, Vol.20 (1), p.764-10, Article 764 [Peer Reviewed Journal]

COPYRIGHT 2020 BioMed Central Ltd. ;COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-020-07263-9 ;PMID: 32795284

Full text available

13
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
Material Type:
Article
Add to My Research

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Annals of oncology, 2019-10, Vol.30 (10), p.1653-1659 [Peer Reviewed Journal]

2019 THE AUTHORS ;The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz288 ;PMID: 31435660

Full text available

14
miRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer
Material Type:
Article
Add to My Research

miRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer

PloS one, 2017-02, Vol.12 (2), p.e0171751-e0171751 [Peer Reviewed Journal]

COPYRIGHT 2017 Public Library of Science ;COPYRIGHT 2017 Public Library of Science ;2017 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2017 Chen et al 2017 Chen et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0171751 ;PMID: 28199399

Full text available

15
Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study
Material Type:
Article
Add to My Research

Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study

PLoS medicine, 2018-11, Vol.15 (11), p.e1002711 [Peer Reviewed Journal]

COPYRIGHT 2018 Public Library of Science ;COPYRIGHT 2018 Public Library of Science ;2018 Hosny et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 Hosny et al 2018 Hosny et al ;ISSN: 1549-1676 ;ISSN: 1549-1277 ;EISSN: 1549-1676 ;DOI: 10.1371/journal.pmed.1002711 ;PMID: 30500819

Full text available

16
Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer
Material Type:
Article
Add to My Research

Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer

BMC immunology, 2018-01, Vol.19 (1), p.3-3, Article 3 [Peer Reviewed Journal]

COPYRIGHT 2018 BioMed Central Ltd. ;COPYRIGHT 2018 BioMed Central Ltd. ;2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2018 ;ISSN: 1471-2172 ;EISSN: 1471-2172 ;DOI: 10.1186/s12865-018-0241-4 ;PMID: 29361917

Full text available

17
Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer
Material Type:
Article
Add to My Research

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

PloS one, 2018-10, Vol.13 (10), p.e0204490-e0204490 [Peer Reviewed Journal]

COPYRIGHT 2018 Public Library of Science ;COPYRIGHT 2018 Public Library of Science ;2018 Schernberg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;2018 Schernberg et al 2018 Schernberg et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0204490 ;PMID: 30304046

Full text available

18
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Material Type:
Article
Add to My Research

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients

Clinical cancer research, 2018-07, Vol.24 (13), p.3097-3107 [Peer Reviewed Journal]

2018 American Association for Cancer Research. ;Copyright American Association for Cancer Research Inc Jul 1, 2018 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-17-2310 ;PMID: 29506987

Full text available

19
Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer
Material Type:
Article
Add to My Research

Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer

BMC cancer, 2024-05, Vol.24 (1), p.569-569 [Peer Reviewed Journal]

2024. The Author(s). ;COPYRIGHT 2024 BioMed Central Ltd. ;2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2024 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-024-12315-5 ;PMID: 38714983

Full text available

20
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Material Type:
Article
Add to My Research

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

The New England journal of medicine, 2018-12, Vol.379 (24), p.2342-2350 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1809697 ;PMID: 30280658

Full text available

Results 1 - 20 of 68,597  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (63,961)

Refine My Results

Creation Date 

From To
  1. Before 1967  (249)
  2. 1967 To 1980  (4,161)
  3. 1981 To 1994  (9,582)
  4. 1995 To 2009  (21,974)
  5. After 2009  (32,696)
  6. More options open sub menu

Subject 

  1. Humans  (68,475)
  2. Science & Technology  (57,805)
  3. Male  (56,514)
  4. Life Sciences & Biomedicine  (54,929)
  5. Female  (54,000)
  6. Middle Aged  (48,704)
  7. Aged  (37,615)
  8. Biological And Medical Sciences  (19,967)
  9. Medical Sciences  (19,183)
  10. Aged, 80 And Over  (15,122)
  11. Respiratory System  (14,800)
  12. Oncology  (13,403)
  13. Adolescent  (11,860)
  14. Lung Neoplasms - Pathology  (10,642)
  15. Retrospective Studies  (10,566)
  16. Lung Cancer  (10,090)
  17. General & Internal Medicine  (8,688)
  18. Young Adult  (8,290)
  19. Prognosis  (8,030)
  20. More options open sub menu

Language 

  1. English  (66,327)
  2. Japanese  (10,334)
  3. French  (589)
  4. Portuguese  (506)
  5. Chinese  (498)
  6. German  (495)
  7. Spanish  (404)
  8. Polish  (161)
  9. Russian  (94)
  10. Turkish  (63)
  11. Norwegian  (50)
  12. Italian  (45)
  13. Serbian  (23)
  14. Swedish  (23)
  15. Korean  (18)
  16. Icelandic  (11)
  17. Ukrainian  (10)
  18. Croatian  (10)
  19. Hungarian  (6)
  20. Afrikaans  (6)
  21. More options open sub menu

Searching Remote Databases, Please Wait